Expert Answer
What does a GLP-1 do besides weight loss?
Quick Answer
Beyond weight, GLP-1s show cardiovascular event reduction that appears partly independent of weight loss (via anti-inflammatory effects), plus emerging signals in addiction - curbing alcohol and compulsive cravings (Attia; Knight via Huberman). The "does it slow aging itself" claim is unproven outside obesity/diabetes, and high doses carry real risks (depression, rare eye issues).
Moderate Consensus
on GLP-1 Agonists overall
What Researchers Say
Covers cardiovascular benefit and off-label use for alcohol/addiction cravings, while stressing that a true geroprotective (anti-aging) effect remains unproven outside obesity/diabetes.
Features Dr. Zachary Knight on cardiac benefits that appear independent of weight loss; his candidate mechanism is suppression of systemic inflammation (the "inflammatory reflex").
Features Dr. Ben Bikman, who acknowledges benefits but flags higher-dose risks including increased depression and rare blindness (NAION).
Argues GLP-1s should not be taken for longevity - the risks and dependency outweigh benefits when root-cause metabolic health is achievable through lifestyle.
Detailed Answer
The weight loss is only part of the story, and the "what else" is where the science gets genuinely interesting - and where the panel splits.
Cardiovascular: Dr. Zachary Knight (via Huberman) explains that the cardiac benefits of GLP-1s appear partly independent of weight loss; his candidate mechanism is the "inflammatory reflex," which suppresses systemic inflammation. Preventive cardiologist Dr. Aaron Mikos (via Attia) adds that they reduce cardiovascular events through blood-pressure, lipid, and anti-atherosclerotic effects, not just blood-sugar lowering.
Addiction: this is one of the better-grounded off-label signals. Attia describes "striking success in silencing cravings" in treatment-refractory alcohol use disorder; addiction psychiatrist Dr. Anna Lembke (via Attia) and Dr. Keith Humphreys (via Huberman) both frame GLP-1s as a promising new frontier for alcohol and compulsive behaviors - a potential "two-for" alongside obesity. Brain-health researchers (Dr. Lisa Mosconi via Attia; Dr. Eric Topol via Hyman) note emerging, early interest in neuroprotection and Alzheimer's, driven by the anti-inflammatory effects.
The honest limits: Attia is careful that a true geroprotective ("slows aging itself") effect is unproven - the data is confined to people with obesity or diabetes, making it hard to isolate. And Dr. Ben Bikman (via Patrick) supplies the counterweight: at higher doses he flags increased depression risk and rare blindness (NAION), calling the drugs a "temporary tool, not a lifetime solution." Hyman goes further, arguing flatly that GLP-1s should not be taken for longevity. So: real and expanding benefits beyond weight, with genuine risks and an unproven anti-aging headline.
Related Questions
Do GLP-1s help the heart?
Yes - they reduce cardiovascular events partly independent of weight loss, likely via anti-inflammatory and blood-pressure/lipid effects (Knight via Huberman; Mikos via Attia).
Can GLP-1s help with alcohol or addiction?
Emerging evidence says yes. Attia reports success curbing alcohol cravings; Lembke and Humphreys call it a promising frontier for compulsive behaviors. Trials are still needed.
Do GLP-1s slow aging?
Unproven. Attia stresses the data is confined to obesity/diabetes, so a true geroprotective effect can't yet be isolated. High doses also carry depression and rare eye-risk signals.
More Questions About GLP-1 Agonists
Precis Pro
Get the exact protocol for GLP-1 Agonists
The answer above is the whole answer — every expert's position, where they disagree, and the timecode behind each one. Nothing on this page is held back.
Pro adds
- The dose each expert actually names, and the form they name with it
- Timing and what they say to take it with, or keep it away from
- The interactions they flag by name
- Chat across 3,500+ expert videos, with a timecode behind every answer
$9/mo · Cancel anytime
Full GLP-1 Agonists Consensus Report
See what all the experts agree and disagree on